Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview
Open Access
- 15 July 2016
- Vol. 2 (2), e000239
- https://doi.org/10.1136/rmdopen-2015-000239
Abstract
Paradoxical adverse events (PAEs) have been reported during biological treatment for chronic immune-mediated diseases. PAEs are defined as the occurrence during biological agent therapy of a pathological condition that usually responds to this class of drug. A wide range of PAEs have been reported including dermatological, intestinal and ophthalmic conditions, mainly with antitumour necrosis factor α (TNF-α) agents. True PAEs include psoriasis, Crohn's disease and hidradenitis suppurativa. Other PAEs may be qualified as borderline and include uveitis, scleritis, sarcoidosis and other granulomatous diseases (granuloma annulare, interstitial granulomatous dermatitis), vasculitis, vitiligo and alopecia areata. Proposed hypotheses to explain these PAEs include an imbalance in cytokine production, the differential immunological properties between the monoclonal antibodies and TNF-α soluble receptor, an unopposed type I interferon production and a shift towards a Th1/Th2 profile. Data from registries suggest that the risk for paradoxical psoriasis is low and non-significant. We discuss management of these PAEs, which depends on the type and severity of the adverse events, pre-existing treated conditions and the possibility of alternative therapeutic options for the underlying disease. Paradoxical adverse events are not restricted to anti-TNF-α agents and close surveillance of new available biological drugs (anti-interleukin-17/23, anti-integrin) is warranted in order to detect the occurrence of new or as yet undescribed events.Keywords
This publication has 80 references indexed in Scilit:
- Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseasesJournal of the American Academy of Dermatology, 2016
- Hidradenitis suppurativa: the role of immune dysregulationInternational Journal of Dermatology, 2014
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis SuppurativaAnnals of Internal Medicine, 2012
- Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for Rheumatoid Arthritis: Data from the French AIR RegistryThe Journal of Rheumatology, 2012
- Vitiligo during Treatment of Crohn’s Disease with Adalimumab: Adverse Effect or Co-OccurrenceCase Reports in Dermatology, 2011
- Severe Skin Lesions Cause Patients With Inflammatory Bowel Disease to Discontinue Anti–Tumor Necrosis Factor TherapyClinical Gastroenterology and Hepatology, 2010
- Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible ImmunopathogenesisSeminars in Arthritis and Rheumatism, 2010
- Do TNF-blockers reduce or induce uveitis?Rheumatology, 2008
- Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanerceptArthritis & Rheumatism, 2007
- Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalphaAnnals Of The Rheumatic Diseases, 2001